Three Trick Pony ?+ another $ 4 ???? The EAA is so misunderstood and undervalued.
It's the linchpin/key companion diagnostic in the theranostic approach to Endotoxemic Sepsis diagnosis and ongoing treatment (see Ronco's the Golden Hour - the world's KOL)
20% of all Global Deaths ?
"Sepsis is a life-threatening complication caused by a dysregulated host response to infection. Sepsis and septic shock remain major healthcare problems. In 2017, there were 48.9 million incident cases of sepsis and 11.0 million sepsis-related deaths worldwide, representing 19.7% of all global deaths"
https://janesthanalgcritcare.biomedcentral.com/articles/10.1186/s44158-022-00056-5
...if only 5 % of the world's Sepsis patients were tested with just one EAA at $ 200 The resulting annual revenue generated would be: 50,000,000 sepsis patients annually x $ 200 x 5% = $ 500 Million high margin USD in additional revenue to the owner of the EAA!
The EAA is the only FDA approved Endotoxin diagnostic and it will be KEY to PMX treatment, and to the diagnosis of Endotxemia, and to knowing when to begin treatment, and when to stop.
Spectral maintains the WORLDWIDE rights. Using the highly conservative penetration assumed above ($ 500M in annual revenues), and assuming 2X sales (cheap for a high margin FDA approved device with no competion), one arrvie at $ 1 B in valuation, and $ 3.33 USD based on 300M share o/s, or > $ 4 CAD added by the EAA. This is not the EAA's used with PMX in the NA alone (assumed in presentations).
We won't veven talk about potential valuation of the EAA if one assumed an average of 3-5 EAA's used and a modest 10% penetration in ICU's worldwide (especially after PMX gets the golden seal of approval from the FDA)
MM